This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

The Deal: DSM, JLL Join to Create Pharma Company

NEW YORK ( The Deal) -- Dutch chemicals and nutrition company Royal DSM NV is to merge its pharmaceuticals division into a new entity majority owned by New York-based private equity firm JLL Partners Inc. to create a company valued at $2.62 billion.

DSM said Tuesday, Nov. 19, that it will combine DSM Pharmaceutical Products, or DPP, with JLL-backed Patheon Inc., after the new entity acquires Patheon for $9.32 per share in cash, or 64% above Patheon's closing share price Monday. The transaction values Patheon at about $1.95 billion, including debt, and DPP at $670 million.

JLL, which owns 55.7% of Patheon, will invest $489 million in cash in the new venture, while DSM will contribute DPP and receive a seller note of $200 million.

To fund the deal, JLL has committed financing for $1.65 billion from JPMorgan Chase & Co., UBS, Jefferies & Co., Morgan Stanley and KeyCorp.

The still-unnamed new entity will be 51% owned by JLL and 49% by DSM and be run by Patheon CEO Jim Mullen. It is projected to have 2014 sales of about $2 billion, with an 8,300-strong workforce in 23 locations across North America, Europe, Latin America and Austria.

The new entity will be a contract development and manufacturing organization selling finished dosages and drug products and active substances to customers in the pharmaceuticals, crop protection, personal care and fine chemicals products industries.

"Fully in line with our strategy, this is for DSM Pharmaceutical Products the perfect way to accelerate growth and for DSM to maximize value for this business," said DSM CEO Feike Sijbesma "With this partnership, DSM has made a key step in its strategic transformation of its Pharma activities into partnerships whilst creating maximum value for all stakeholders."

JLL Partners Managing Director Paul S. Levy led the deal for the buyout firm.

DSM shares rose 3.35% to €59.91 in Amsterdam, giving it a market value of nearly €10.9 billion. The stock is up 51.34% over a year ago. Patheon shares closed at C$5.95 ($5.70) in Toronto on Monday.

JLL Partners, which typically targets mid-market investments in North America, has committed about $4.2 billion across six funds, made its initial investment in Patheon in 2007. Patheon's board backs the deal, which was vetted by independent directors. The company is incorporated and traded in Toronto but has corporate head offices in Durham, N.C.

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
AAPL $130.28 0.00%
FB $81.53 0.00%
GOOG $565.06 0.00%
TSLA $218.42 0.00%
YHOO $44.52 0.00%


DOW 18,080.14 +21.45 0.12%
S&P 500 2,117.69 +4.76 0.23%
NASDAQ 5,092.0850 +36.0220 0.71%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs